LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 05, 2025 08:00 ET Â | Source: LENZ Therapeutics, Inc. VIZZTM (aceclidine…
Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa
DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive…
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025 16:30 ET Â | Source: FibroBiologics, Inc. Advancing preparations to…
Star Health Reports 21% YoY Profit Growth to 518 Cr; COR Improves by 170 bps in H1FY26 under IFRS
24% growth in fresh retail premiums Expense ratio improves to 29.7% from…
ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ --Â ACMÂ Biolabs, a clinical-stage biotechnology company developing next-generation…
Akums Reports Q4 FY25 with 12.4% Revenue Growth, FY25 Adj. EBITDA Remained Strong at 12.3%
Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organization…
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinsons disease
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at…
ACKO’s Grand Traffic Challan Report: Delhi Leads E Challan Fines
NEW DELHI, Oct. 6, 2025 /PRNewswire/ -- ACKO's Grand Traffic Challan Report…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025 16:01 ET Â | Source: BridgeBio Pharma, Inc. PALO ALTO,…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025 16:01 ET Â | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass.,…